What we're reading, June 24, 2016: Britain's decision to leave the European Union will impact drug regulation; Supreme Court decision derails California proposal to allow illegal immigrants to buy health insurance; and lawmakers look to reduce exclusivity period for biologics.
Britain has opted to leave the European Union (EU), which can impact drug regulation in the United Kingdom and the EU. The European Medicines Agency approves treatments for all EU countries, but is based in London, and now it is expected to have to relocate, reported Reuters. There is uncertainty about the exact effect that Britain leaving the EU will have on the EU’s drug approval process, but now Britain may have to develop its own regulatory system.
The Supreme Court’s decision to block President Obama’s immigration programs will impact legislation in California. According to the Los Angeles Times, California legislators have been fighting to offer health insurance to people living in the country illegally, but the new ruling stalls those efforts. If the program had been implemented, 621,000 people could have qualified for Medi-Cal, but instead as many as 1.5 million of the state’s illegal immigrants could remain uninsured. This population will represent approximately half of California’s total uninsured population.
A lawmaker is looking to reduce the exclusivity period for expensive biologic medicines. A new bill would shorten the exclusive amount of time companies have for biologics from 12 years to just 7 years, reported STAT. The purpose of the legislation is to allow biosimilars to be marketed sooner in an attempt to reduce healthcare expenses in the United States. A bill was introduced by a Democrat in the House on Thursday, and 2 Republicans are expected to introduce a companion bill in the Senate.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Commonwealth Fund Report Details Pervasive Racial and Ethnic Disparities in US Health Care, Outcomes
April 18th 2024Using 25 health system performance indicators, the Commonwealth Fund 2024 State Health Disparities Report evaluated racial and ethnic disparities in health care and health outcomes both within and across US states and highlighted the urgent need for equitable health care policies and practices in the US.
Read More